Published by Coherent Market Insights
Posted on September 20, 2021
Coherent Market Insights released a new market study on 2021-2027 Influenza Vaccines Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2021-2027 Influenza Vaccines Market Forecast till 2027*.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/1705
The rapid spread of influenza virus around the world has increased the demand for safe and efficient influenza vaccine, driving the influenza vaccines market growth. According to the United States Centers for Disease Control and Prevention (CDC), influenza has resulted in between 9 million to 45 million illnesses, between 140,000 to 810,000 hospitalizations, and between 12,000 to 61,000 deaths every year since 2010. Influenza is a viral infection that attacks the respiratory system. It is a contagious respiratory infection caused due to influenza virus. Illness due to the infection ranges from mild to severe, occasionally leading to death. Influenza vaccines protect against infection caused by influenza viruses.
Therefore, there is an increasing demand for influenza vaccines around the world. However, new versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. In June 2021, the National Institutes of Health (NIH) begun a phase 1 human trial studying a universal influenza vaccine, FluMos-v1. The vaccine was developed by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and is designed to stimulate antibodies against multiple strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds. The disease occurs worldwide and spreads very quickly in populations, especially in crowded circumstances.
Thus, growth of the influenza vaccines market is driven by the increasing burden of influenza disease worldwide, especially in North America and the Asia Pacific. Seasonal Influenza may affect all age groups; globally incidence is higher in young children and those above 65 years. In February 2020, Abbott launched a new inactivated quadrivalent vaccine for influenza, the first of its kind sub-unit vaccine offering protection against four virus strains, in India. It is the only vaccine in India that has been approved for use in children below 3 years. This in turn is also expected to accelerate the growth of the influenza vaccines market in India.
According to the World Health Organization (WHO), vaccination is a vital tool help prevent the infection and severe outcomes caused by influenza viruses. It helps protect women during pregnancy and their babies up to six months and among vaccinated, reduction in influenza related hospitalizations across all age groups is expected. Thus, with the increasing awareness among people about the vaccination, the demand for influenza vaccines is also increasing with a rapid pace. However, continuous mutation in genetic structure of influenza virus result in emergence of new virus, which remain unaffected by currently available vaccines. This in turn is expected to hamper the influenza vaccines market growth.
Influenza Vaccines Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Seqirus Vaccines Limited, GlaxoSmithKline plc, ID Biomedical Corporation, Sanofi, Protein Sciences Corp., and MedImmmune LLC
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1705
Reasons to Purchase this Report
• Current and future of global Influenza Vaccines Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Major Point Answered in Influenza Vaccines Market Research Study are:
Request Here Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/1705
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post The influenza vaccines market was valued to be US$ 3,991.4 million in 2020 and is expected to witness a CAGR of 4.4% over the forecast period (2021 – 2027). appeared first on Gatorledger.
Coherent Market Insights released a new market study on 2021-2027 Influenza Vaccines Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2021-2027 Influenza Vaccines Market Forecast till 2027*.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/1705
The rapid spread of influenza virus around the world has increased the demand for safe and efficient influenza vaccine, driving the influenza vaccines market growth. According to the United States Centers for Disease Control and Prevention (CDC), influenza has resulted in between 9 million to 45 million illnesses, between 140,000 to 810,000 hospitalizations, and between 12,000 to 61,000 deaths every year since 2010. Influenza is a viral infection that attacks the respiratory system. It is a contagious respiratory infection caused due to influenza virus. Illness due to the infection ranges from mild to severe, occasionally leading to death. Influenza vaccines protect against infection caused by influenza viruses.
Therefore, there is an increasing demand for influenza vaccines around the world. However, new versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. In June 2021, the National Institutes of Health (NIH) begun a phase 1 human trial studying a universal influenza vaccine, FluMos-v1. The vaccine was developed by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and is designed to stimulate antibodies against multiple strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds. The disease occurs worldwide and spreads very quickly in populations, especially in crowded circumstances.
Thus, growth of the influenza vaccines market is driven by the increasing burden of influenza disease worldwide, especially in North America and the Asia Pacific. Seasonal Influenza may affect all age groups; globally incidence is higher in young children and those above 65 years. In February 2020, Abbott launched a new inactivated quadrivalent vaccine for influenza, the first of its kind sub-unit vaccine offering protection against four virus strains, in India. It is the only vaccine in India that has been approved for use in children below 3 years. This in turn is also expected to accelerate the growth of the influenza vaccines market in India.
According to the World Health Organization (WHO), vaccination is a vital tool help prevent the infection and severe outcomes caused by influenza viruses. It helps protect women during pregnancy and their babies up to six months and among vaccinated, reduction in influenza related hospitalizations across all age groups is expected. Thus, with the increasing awareness among people about the vaccination, the demand for influenza vaccines is also increasing with a rapid pace. However, continuous mutation in genetic structure of influenza virus result in emergence of new virus, which remain unaffected by currently available vaccines. This in turn is expected to hamper the influenza vaccines market growth.
Influenza Vaccines Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Seqirus Vaccines Limited, GlaxoSmithKline plc, ID Biomedical Corporation, Sanofi, Protein Sciences Corp., and MedImmmune LLC
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1705
Reasons to Purchase this Report
• Current and future of global Influenza Vaccines Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Major Point Answered in Influenza Vaccines Market Research Study are:
Request Here Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/1705
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post The influenza vaccines market was valued to be US$ 3,991.4 million in 2020 and is expected to witness a CAGR of 4.4% over the forecast period (2021 – 2027). appeared first on Gatorledger.
Explore more articles in the Research Reports category
